Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

This is a prospective non-randomised Phase I/II study with patients recruited to escalated dose cohorts. Escalated dose to the iGTV (internal gross tumour volume), with 60 Gy to the conventional PTV (planning target volume), will be delivered to successive cohorts of participants (6-12 participants/cohort) until the maximum tolerated oesophageal dose is determined. The minimum dose will be 60 Gy delivered via intensity modulated radiation therapy (IMRT) or volume modulated arc therapy (VMAT), planned on an Average Intensity Projection (AVIP) dataset.

Standard of care chemotherapy.

There will be two treatment arms; one with patients who are planned to receive neo-adjuvant or no chemotherapy, and the other with patients who are planned to receive concurrent chemotherapy

Patient Profile

Where’s this trial being run?

St Luke’s Radiation Oncology Network @ St James’s Hospital and St Luke’s Radiation Oncology Network @ St Luke’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: INTENSE
Number: 15-47
Full Title:

A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer

Principal Investigator: Professor John Armstrong
Type: In-House
Sponsor:

Cancer Trials Ireland

Recruitment Started: Global: N/A
Ireland: Q2 2017
Global Recruitment Target: N/A
Ireland Recruitment Target: 104